Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD versus MAYZENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD versus MAYZENT.
FINGOLIMOD vs MAYZENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.
0.5 mg orally once daily
0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Clinical Note
moderateFingolimod + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Isavuconazonium
Terminal elimination half-life is approximately 8–10 days due to slow dissociation from sphingosine 1-phosphate receptors; steady-state reached in 3–4 weeks.
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Primarily fecal (≈76% as metabolites) and renal (≈24% as metabolites and minor unchanged drug).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator
"The metabolism of Isavuconazonium can be decreased when combined with Fingolimod."